Background: Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized by insulin deficiency due β-cell destruction and following hyperglycaemia. Specific markers of T1DM are pancreatic islet-targeting autoantibodies that are found months to years before symptom onset, and can be used to identify individuals who are at risk of developing T1DM. Aim: The study is aimed at the review of current knowledge of diabetes-related autoantibodies as biomarkers of T1DM. Materials and methods : Foreign and national clinical studies on this topic were included. PubMed, Medline and eLibrary were searched. Results: Modern ideas about known diabetes-specific autoantibodies as markers of autoimmune inflammation of β-cells of the pancreas were discussed. The analysis of their independent diagnostic value in predicting the occurrence of T1DM were carried out. Conclusion: There is no unified concept in the literature on this issue. Current data on autoantibodies in T1DM show a significant individual variability in the timing, dynamic changes and autoantibody composition in T1DM progression.
No takes yet. Share an insight, caveat, or question.
Корнева et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: